Abstract:Chronic kidney disease (CKD) is a growing public health concern, affecting at least 1 in 7 adults in the United States, and accounting for a large proportion of healthcare spending. The risk of mortality rises steeply with declining kidney function, mostly due to cardiovascular-related deaths. Since CKD is asymptomatic in the early stages, diagnosis is sometimes delayed. However, early diagnosis is important for timely initiation of interventions to reduce disease progression, and to avoid the need for hospitalizations, dialysis, or kidney transplantation. This review focuses on the impact of sodium glucose transporter 2 inhibitors (SGLT2i) on CKD based on mechanistic and clinical trial evidence. These agents affect the kidneys through changes in sodium transport and metabolic factors that interfere with the primary pathological mechanisms shared by most kidney diseases. Following clinical trials of SGLT2i in patients with type 2 diabetes which demonstrated reductions in the risk of major adverse CV events, death, and hospitalizations for heart failure (HHF), and in patients with heart failure (HF) with and without diabetes which showed reductions in death and HHF, recent trials in patients with CKD have provided overwhelming support for the use of SGLT2i as foundational therapy across a broad spectrum of patients with CKD, regardless of diabetes status, primary kidney disease (except polycystic kidney disease), or kidney function. While clinical trials in CKD generally recruit patients with a high risk of events, patients at lower risk could also benefit from SGLT2i in terms of reduction of CKD progression, HF, and death, as well as other beneficial effects including reductions in blood sugar, body weight, and blood pressure. Chronic kidney disease (CKD) is a serious health problem that affects at least 1 in 7 adults in the United States. However, around 9 out of 10 adults with CKD are not aware that they have the condition. This is because people with CKD often have no symptoms, especially in the early stages of their condition. People with CKD have a higher risk of death and heart and/or kidney complications compared with people without the condition. It is important that doctors diagnose CKD as early as possible, so they can advise people about lifestyle changes and treatments that help to slow the progression of their CKD. Early diagnosis and intervention can reduce the chance that someone with CKD will be admitted to the hospital or eventually need dialysis or a kidney transplant. This article looked at a group of medicines called sodium-glucose cotransporter 2 (SGLT2) inhibitors that can be used to treat people with CKD. SGLT2 inhibitors were first developed to treat people with type 2 diabetes (T2D); however, further research has shown that these medicines can help to protect the kidneys and the heart in people with CKD with and without T2D. SGLT2 inhibitors can help to slow the decline in kidney function and lower the risk of death and hospitalizations in people with CKD. Research has shown that a wide range of people with CKD could benefit from treatment with SGLT2 inhibitors. This article describes how SGLT2 inhibitors can affect the body and the benefits of these medicines in people with CKD.

SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment

Elevated Serum Magnesium Associated with SGLT2 Inhibitor Use in Type 2 Diabetes Patients: a Meta-Analysis of Randomised Controlled Trials

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence

Higher serum magnesium levels associated with the use of sodium – glucose cotransporter 2 ( SGLT 2 ) inhibitors among type 2 diabetes patients : a meta-analysis of randomized controlled trials

A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease

Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease

Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis

Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis

The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus

Sodium/Glucose Cotransporter 2 Inhibitors and Magnesium Homeostasis

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review

Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center

SGLT-2 inhibitors and nephrolithiasis risk: a meta-analysis

Lower heart failure and chronic kidney disease risks associated with sodium‐glucose cotransporter‐2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases

Sodium–Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome

Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?

Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors

SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study